Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

NCT03811457 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma Leukemia

Interventions

GENETIC: Welgenaleucel

Sponsor

UWELL Biopharma

Collaborators

[object Object]